Organigram Global Inc. revenue

Organigram Global Inc.'s revenue was $185m in fiscal 2025, up 57.8% on the year before. Since fiscal 2018 ($9.7m) it has grown at a compound 52.4% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Organigram Global Inc.: revenue history, annual
Fiscal year	2018Aug 2018	2019Aug 2019	2020Aug 2020	2021Aug 2021	2022Aug 2022	2023Sept 2023	2024Sept 2024	2025Sept 2025
Revenue	10	61	65	62	115	120	117	185
Growth on the year before	—	+523.6%	+6.3%	−3.2%	+83.6%	+4.6%	−2.1%	+57.8%
Gross profit	40	37	−42	−22	25	28	35	65
Gross margin	—	60.3%	−65.1%	−35.9%	21.7%	23.5%	29.7%	34.8%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Organigram Global Inc.	$185m	57.8%	—
Biote Corp.	$184m	-7.8%	0.5%
Kamada LTD	$180m	12.1%	—
Cronos Group Inc.	$179m	37.5%	30.3%
Amarin Corp plc\uk	$176m	-22.3%	-18.3%
Heron Therapeutics, Inc.	$151m	1.0%	8.6%

Compare with peers

Head to head: BTMD vs OGI KMDA vs OGI CRON vs OGI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Organigram Global Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Organigram Global Inc.